Previous 10 | Next 10 |
Triggering mucosal immunity may be crucial for effective protection against SARS-CoV-2 infection and transmission Vaxart’s oral tablet vaccine can overcome major challenges of injectable vaccines SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (...
One or more drugmakers with COVID-19 vaccines in development could make a fortune very soon. The global market for vaccines against the novel coronavirus could reach $20 billion next year. When companies make fortunes, their investors can too. How should you invest in coronavirus vaccine stocks...
A coronavirus vaccine would arguably save countless lives and help economies around the world recover from a recession through herd immunity. As a result, everyone in the investment world is talking about biotechs that are scrambling to develop a vaccine against SARS-CoV-2, the coronavirus that...
It's been a while since I went through the whole vaccine landscape (I've been putting it off!), but there's a lot to catch up on. I'm going to incorporate some slightly reworked material from my July post in the introduction to each vaccine class, for reference, but everything on the candida...
- H.C. Wainwright: 22 nd Annual Global Investment Conference - September 14 th – 16 th - Sachs Associates: 20 th Annual Biotech in Europe Forum - September 21 st – 24 th - SVB Leerink: CybeRx Series: Vaccine Forum - September 23 rd & – 24 th SOU...
Sanofi (NASDAQ: SNY ) and GlaxoSmithKline (NYSE: GSK ) have started the Phase 1/2 clinical trial for their COVID-19 adjuvanted recombinant protein-based vaccine candidate. More news on: Sanofi, GlaxoSmithKline plc, Vaxart, Inc., Healthcare stocks news, Read more .....
Gainers: Corcept Therapeutics (NASDAQ: CORT ) +35% . More news on: Corcept Therapeutics Incorporated, Vera Bradley, Inc., NanoViricides, Inc., Stocks on the move, , Read more ...
Inovio Pharmaceuticals (NASDAQ: INO ) , up 245% in 2020, is off more than 12% Wednesday as short seller Muddy Waters discloses they are short the name, citing a recent court decision against the company and its recent rise due to the "hype" around a Covid vaccine. More news on: Inovio ...
Investment Thesis The stock prices of biotechs developing vaccine solutions for COVID-19 have declined markedly over the past couple of weeks, despite the need for a coronavirus cure being greater than ever. Performance of selected biotech vaccine/adjuvant developers Vaxart, Moderna, Novav...
One of my investments is in a small COVID vaccine company, Heat Biologics ( HTBX ), and I generally route for the little guy. So I don't particularly like writing an article that has a number of facts and reasons why probably none of the remaining small players are going to become major player...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...